Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.

Primary outcomes The primary endpoint of change in radial trabecular vBMD from baseline at month 12 did not reach statistical significance ( Table 2 ).

also in 111,027 other papers